SAB Biotherapeutics (NASDAQ:SABS) Upgraded at Wall Street Zen

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday.

SABS has been the subject of a number of other research reports. Leerink Partners upped their price objective on SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, June 15th. Barclays initiated coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 target price on the stock. Chardan Capital boosted their target price on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $13.00 price target on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SAB Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

SAB Biotherapeutics Price Performance

Shares of SABS stock opened at $3.51 on Friday. SAB Biotherapeutics has a 52-week low of $1.85 and a 52-week high of $5.15. The stock has a market cap of $268.37 million, a PE ratio of -1.66 and a beta of 0.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The firm’s 50 day moving average price is $3.69 and its two-hundred day moving average price is $3.84.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). As a group, analysts forecast that SAB Biotherapeutics will post -1.19 EPS for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. acquired a new position in SAB Biotherapeutics in the 1st quarter worth $29,000. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at about $34,000. State Street Corp bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $49,000. Fifth Lane Capital LP bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $56,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter worth about $30,000. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.